Stocks
JPMorgan Chase Initiates Coverage on BlossomHill Therapeutics with Overweight Rating
JPMorgan Chase & Co. has initiated coverage on BlossomHill Therapeutics (NASDAQ:BLSM), assigning an 'overweight' rating and a price target of $28.00.
This move indicates a potential upside of 53.01% from the stock's previous close, which was $18.30 on Tuesday.
BlossomHill Therapeutics has been the subject of multiple research reports in recent months, with Wall Street Zen upgrading its rating to 'hold' and Guggenheim issuing a 'buy' rating with a target price of $30.00.